Literature DB >> 11803160

Bioartificial kidney alters cytokine response and hemodynamics in endotoxin-challenged uremic animals.

William H Fissell1, D Brad Dyke, William F Weitzel, Deborah A Buffington, Angela J Westover, Sherrill M MacKay, Jorge M Gutierrez, H David Humes.   

Abstract

The mortality from sepsis complicated by renal failure remains extremely high despite the application of modern renal replacement therapy. This study investigated whether treatment with a bioartificial kidney consisting of a hemofilter in a continuous venovenous hemofiltration circuit (CVVH) with a cartridge containing renal proximal tubule cells, also called the Renal Tubule Assist Device (RAD), would alter the course of sepsis in an animal model. The RAD has been previously characterized in vitro and ex vivo and provides transport, metabolic and endocrine activity. Mongrel dogs (n = 10) underwent surgical nephrectomy and 48 h later were treated with CVVH and either a RAD containing cells (n = 5) or an identically prepared sham cartridge (n = 5). After 4 h of therapy, intravenous endotoxin 2 mg/kg was infused over 1 h to simulate gram-negative septic shock. Data on blood pressure, cardiac output and systemic markers of inflammation were collected. Mean peak levels of an anti- inflammatory cytokine, IL-10, were significantly higher in cell-treated animals (15.25 vs. 6.29 ng/ml; p = 0.037), and mean arterial pressures were higher in cell-treated versus sham-treated animals (p < 0.04). We have demonstrated that treatment of an animal model of endotoxin shock and renal failure with a bioartificial kidney has measurable effects on circulating mediators of inflammation and on hemodynamic stability of the challenged animal. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11803160     DOI: 10.1159/000046986

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  16 in total

Review 1.  Cell therapy, advanced materials, and new approaches to acute kidney injury.

Authors:  Alexander S Yevzlin; H David Humes
Journal:  Hosp Pract (1995)       Date:  2009-12

Review 2.  Enabling innovative translational research in acute kidney injury.

Authors:  Abolfazl Zarjou; Paul W Sanders; Ravindra L Mehta; Anupam Agarwal
Journal:  Clin Transl Sci       Date:  2011-12-07       Impact factor: 4.689

Review 3.  Pathophysiology of acute kidney injury.

Authors:  David P Basile; Melissa D Anderson; Timothy A Sutton
Journal:  Compr Physiol       Date:  2012-04       Impact factor: 9.090

4.  A bio-artificial renal epithelial cell system conveys survival advantage in a porcine model of septic shock.

Authors:  Angela J Westover; Deborah A Buffington; Kimberly A Johnston; Peter L Smith; Christopher J Pino; H David Humes
Journal:  J Tissue Eng Regen Med       Date:  2014-11-25       Impact factor: 3.963

Review 5.  Renal cell therapy and beyond.

Authors:  Joon Ho Song; H David Humes
Journal:  Semin Dial       Date:  2009 Nov-Dec       Impact factor: 3.455

Review 6.  The bioartificial kidney: current status and future promise.

Authors:  H David Humes; Deborah Buffington; Angela J Westover; Shuvo Roy; William H Fissell
Journal:  Pediatr Nephrol       Date:  2013-04-26       Impact factor: 3.714

Review 7.  The bioartificial kidney in the treatment of acute kidney injury.

Authors:  Joon Ho Song; H David Humes
Journal:  Curr Drug Targets       Date:  2009-12       Impact factor: 3.465

8.  Stem cells: the next therapeutic frontier.

Authors:  H David Humes
Journal:  Trans Am Clin Climatol Assoc       Date:  2005

9.  Achievements and challenges in bioartificial kidney development.

Authors:  Farah Tasnim; Rensheng Deng; Min Hu; Sean Liour; Yao Li; Ming Ni; Jackie Y Ying; Daniele Zink
Journal:  Fibrogenesis Tissue Repair       Date:  2010-08-10

10.  Generation of easily accessible human kidney tubules on two-dimensional surfaces in vitro.

Authors:  Huishi Zhang; Samantha Fong-Ting Lau; Ber Fong Heng; Pei Yun Teo; P K D Thilini Alahakoon; Ming Ni; Farah Tasnim; Jackie Y Ying; Daniele Zink
Journal:  J Cell Mol Med       Date:  2010-06-25       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.